A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells

Chem Commun (Camb). 2013 Aug 28;49(67):7442-4. doi: 10.1039/c3cc44508a.

Abstract

Herein, we report the preparation of genetically engineered protein cages (HspG41C-SP94), taken up selectively by human hepatocellular carcinoma (HCC) cells. An engineered protein cage-doxorubicin (DOX) conjugate was as cytotoxic as free DOX against HCC cells but much less cytotoxic against normal hepatocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / pharmacology
  • Archaeal Proteins / chemistry*
  • Archaeal Proteins / genetics
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / pathology
  • Cell Line, Tumor
  • Doxorubicin / administration & dosage*
  • Doxorubicin / pharmacology
  • Drug Carriers / chemistry
  • Heat-Shock Proteins, Small / chemistry*
  • Heat-Shock Proteins, Small / genetics
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Methanocaldococcus / chemistry*
  • Methanocaldococcus / genetics
  • Models, Molecular
  • Molecular Sequence Data
  • Nanostructures / chemistry
  • Protein Engineering

Substances

  • Antibiotics, Antineoplastic
  • Archaeal Proteins
  • Drug Carriers
  • Heat-Shock Proteins, Small
  • Doxorubicin